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Abstract. Endometriosis is a well-known risk factor for 
ovarian cancer. The genetic changes that characterise endome-
triosis are poorly understood; however, the mechanistic target 
of rapamycin (mTOR) pathway is involved. In this study, we 
investigated the expression of key mTOR components in endo-
metriosis and the effects of rapalogues using an endometrioid 
ovarian carcinoma cell line (MdAH 2774) as an in vitro model. 
Gene expression of mTOR, dEPTOR, Rictor and Raptor was 
assessed by qPcR in 24 endometriosis patients and in silico in 
ovarian cancer patients. Furthermore, the effects of Rapamycin, 
Everolimus, deforolimus, Temsirolimus, Resveratrol, and 
BEZ235 (dactolisib, a dual kinase inhibitor) on mTOR signal-
ling components was assessed. mTOR showed a significant 
increase in the expression in endometriosis and ovarian endo-
metrioid adenocarcinoma patients compared to non-affected 
controls. dEPTOR, an inhibitor of mTOR, was downregulated 
in the advanced stages of ovarian cancer (III and IV) compared 
to earlier stages (I and II). Treatment of MdAH-2774 cells with 
the mTOR inhibitors resulted in the significant upregulation 
of dEPTOR mRNA, whereas treatment with rapamycin and 
BEZ-235 (100 nM) resulted in downregulation of the mTOR 
protein expression after 48 h of treatment. None of the treat-
ments resulted in translocation of mTOR from cytoplasm to 
nucleus. Upregulation of dEPTOR is a positive prognostic 
marker in ovarian cancer and is increased in response to 
mTOR pathway inhibition suggesting that it functions as a 
tumour suppressor gene in endometrioid ovarian carcinoma. 
collectively, our data suggest the mTOR pathway as a potential 
connection between endometriosis and ovarian cancer and may 
be a potential target in the treatment of both conditions.
Introduction
Endometriosis is a non-malignant condition characterised by the 
ectopic implantation and growth of endometrial tissue in loca-
tions within the abdominal cavity, such as the fallopian tubes, 
ovaries, peritoneum, vagina, bladder, bowel and rectum. Ectopic 
endometrium responds to hormonal changes in the same way 
as eutopic endometrium, by proliferating and shedding with the 
menstrual cycle causing pain and inflammation in the affected 
areas. Symptoms of endometriosis include dysmenorrhea, 
dyspareunia, dysuria, dyschezia, infertility and chronic pelvic 
pain as well as an increased risk of allergies, asthma, fibromy-
algia, autoimmune disease, hypothyroidism, multiple sclerosis 
and chronic fatigue syndrome (1,2). Endometriosis is estimated 
to affect around two million individuals in the UK (2).
Endometriosis is now becoming a well-documented risk 
factor for ovarian cancer, occurring in up to 28% of ovarian 
cancer patients (3-13). A 20-year study by Stewart et al, of more 
than 21,000 patients seeking fertility treatment in Western 
Australia has shown that endometriosis is particularly associ-
ated with an increased rate of ovarian cancer in patients who 
remained childless after fertility treatment (4). The study did 
not classify invasive epithelial ovarian cancer any further; 
however, a similarly large pooled analysis of 13 ovarian cancer 
risk factor studies examined the relationship between endome-
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triosis and the four major subtypes of epithelial ovarian cancer: 
serous (high and low grade), clear cell, endometrioid and 
mucinous (4). They found that the association between endome-
triosis and ovarian cancer differed between subtypes. Patients 
with low-grade serous (9.2%), endometrioid (13.9%) and clear 
cell (20.2%) subtypes were more likely to have endometriosis 
(compared to 6.2% of control cases). Mucinous epithelial 
ovarian cancer was not at all associated with endometriosis (5). 
In the aforementioned studies, there was no increased risk of 
ovarian cancer in patients with pelvic inflammatory disorder, 
ovarian cysts, fibroids, breastfeeding, weight, height, body‑mass 
index and tubal ligation, highlighting the unique relationship 
between endometriosis and ovarian cancer (4,5,9).
The mTOR pathway is a central regulator of growth, prolif-
eration, apoptosis and angiogenesis providing balance between 
cellular resources such as amino acids and growth factors and 
stresses such as hypoxia to control cellular behaviour accord-
ingly. The activities of this pathway are mediated through the 
mTOR complex 1 (mTORc1) and mTOR complex 2 (mTORc2). 
mTORc1 contains mTOR, Raptor, dEPTOR, GBL and PRAS 
40. mTORc2 contains mTOR, Rictor, dEPTOR and GBL. 
mTOR is a serine/threonine kinase and is the central catalytic 
component of mTORc1 and mTORc2. dEPTOR is a compo-
nent that inhibits the activities of both mTORc1 and mTORc2 
by direct interaction with mTOR. Raptor is a protein component 
of mTORc1 only and controls mTOR kinase activity. Rictor 
is a component of mTORc2 only. The pathways, including 
upstream regulators and downstream effectors of mTORc1 and 
mTORc2 are shown in Fig. 1, in an abbreviated manner. The 
mTOR pathway is inhibited via Rapamycin, also known as siro-
limus, which was first described in 1975. Since its discovery, a 
host of semi-synthetic Rapamycin-related mTORc1 inhibitors 
known as rapalogues, including Everolimus, deforolimus and 
Temsirolimus have been developed. Besides these, dual mTOR 
and PI3K inhibitors such as NVP-BEZ235 and Resveratrol 
have also gained attention (14-16).
The genetic changes that characterise endometriosis are 
poorly understood; however, the mTOR pathway is involved in 
several ways. Leconte et al, showed an increased expression of 
Akt and p70S6K in both the eutopic endometrium and endometri-
otic lesion of patients with deep infiltrating endometriosis (DIE) 
in comparison to the control endometrium (17). Afshar et al, 
showed changes in 23 PI3K/Akt pathway-related genes and 26 
MAP kinase pathway-related genes in the eutopic endometrium 
of baboons with endometriosis (18). Both the PI3K and MAP 
kinase pathways can inactivate the TSc1/TSc2 complex causing 
a release of its inhibitory effect on mTOR kinase activity (19-21). 
Guo et al, identified higher phosphorylated mTOR in ectopic 
endometrium than in eutopic or control endometria (22).
due to its involvement in growth factor and energy sensing 
and its effect on protein synthesis and cell cycle progression, 
the mTOR pathway is involved in a range of malignancies. 
Although there is evidence for the involvement of the mTOR 
pathway in endometriosis and ovarian cancer, its role in the 
transformation from one condition to the other is poorly under-
stood. In the present study, we examined the expression of key 
mTOR components in endometriosis and ovarian cancer and 
used an ovarian cancer cell line of endometrioid origin as a 
preclinical model to dissect further the mechanisms of action 
of mTOR inhibitors.
Materials and methods
Clinical samples. Tissue samples from patients with endome-
triosis (n=24), and non-affected controls (n=34) were obtained 
at the First department of Obstetrics and Gynaecology, 
‘Papageorgiou’ Hospital, University of Thessaloniki, 
Thessaloniki, Greece. Ethical approval was obtained by the 
Ethics committee of Papageorgiou Hospital. For the circu-
lating tumour cell (cTc) study, ovarian cancer blood samples 
(n=3) were collected from ovarian cancer patients enrolled on 
a clinical trial at Mount Vernon Hospital, London, UK, known 
as cIcATRIx. The present study was also approved by the 
National Research Ethics committee and the Research and 
development department of East and North Hertfordshire 
NHS Trust (26/7/16-present).
Written informed consent was obtained from all the patients. 
Patients were stage III/IV ovarian serous adenocarcinoma, and 
enrolled on the trial to begin third-line dual chemotherapy treat-
ment. We confirm that all participants of this study from both 
clinical settings have given their consent regarding inclusion of 
material pertaining to themselves, as specified in the Declaration 
of Helsinki. None of the patients and controls can be identified 
via this manuscript as all cohorts are fully anonymized.
RNA isolation, cDNA synthesis and quantitative RT‑PCR. 
RNA was extracted from tissue lysate using the GenElute™ 
mRNA MiniPrep kit (Sigma-Aldrich; Merck KGaA, 
darmstadt, Germany). cdNA was synthesised from 
mRNA using Superscript II (Invitrogen; Thermo Fisher 
Scientific, Massachusetts, MN, USA). cDNA concentration 
was normalised using RNA concentrations determined by 
NanoDrop (Thermo Fisher Scientific, Pittsburgh, PA, USA). 
Relative expression of the genes of interest was assessed by 
quantitative PcR (qPcR) on an xxpress® (BJS Biotechnologies, 
Middlesex, UK) using Kapa SYBR Fast Universal Master Mix 
(KapaBiosystems-Sigma-Aldrich; Merck KGaA). Primers for 
mTOR, DEPTOR, Rictor and Raptor and qRT‑PCR quantifi-
cation were used as previously described (23). The following 
primers were used as housekeeping genes: YWHAZ, forward: 
5'-aga cgg aag gtg ctg aga aa-3', and reverse: 5'-gaa gca ttg ggg atc 
aag aa-3'; and RPL13A, forward: 5'-cct ggt ctg agc cca ata aa-3' 
and reverse: 5'-ctt gct ccc agc ttc cta tg-3'.
Tissue microarray. Paraffin-embedded ovarian tissue 
microarray slides each containing 70 clinical samples were 
purchased from US Biomax (Rockville, Md, USA). The 
slides were deparaffinised and rehydrated, followed by antigen 
retrieval. Blocking was carried out with 5% goat serum, 
followed by 24-h incubation with primary rabbit monoclonal 
antibodies for mTOR (catalog no. 2983, cell Signalling 
Technology, Inc., danvers, MA, USA; dilution 1:200), and 
dEPTOR (catalog no. 11816, cell Signalling Technology, Inc.; 
dilution 1:200). Following numerous washes with PBS, the 
slides were incubated with HRP-conjugated secondary anti-
body for 60 min. The slides were then washed and subjected to 
dAB staining, counterstained with haematoxylin and washed 
with 0.1% sodium bicarbonate. The slides were then analysed 
for immunoreactivity of both proteins by light microscope 
(Zeiss, Jena, Germany) and positive results were measured by 
the percentage of positive tumour cells.
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Cell line and treatments. MdAH-2774 cells were purchased 
from ATcc and are human ovarian endometr ioid 
adenocarcinoma-derived. MdAH-2774 cells were grown 
in dMEM (dulbecco's Modified Eagle's medium; Life 
Technologies; Thermo Fisher Scientific) supplemented with 
10% FBS (Life Technologies; Thermo Fisher Scientific), 
1% penicillin/streptomycin (Life Technologies; Thermo 
Fisher Scientific) and 1% L‑glutamine (Life Technologies; 
Thermo Fisher Scientific). MDAH‑2774 cells were cultured 
at 37˚C at 5% CO2. We studied the effect of mTOR pathway 
inhibition on the gene expression of mTOR, Rictor, dEPTOR, 
Raptor in vitro using six inhibitory agents: Rapamycin 
(Sigma-Aldrich; Merck KGaA), Everolimus (Sigma-Aldrich; 
Merck KGaA), deforolimus (Selleckchem, Houston, TX, USA), 
Temsirolimus (Sigma-Aldrich; Merck KGaA), NVP-BEZ235 
(Selleckchem) and resveratrol (Sigma-Aldrich; Merck KGaA). 
Treatments were applied in varying concentrations as given in 
Table I for 24, 48 and 72 h.
Immunofluorescence. Following treatments, MdAH-2774 
cells were fixed for 10 min in 4% paraformaldehyde, followed 
by incubation with 10% bovine serum albumin (BSA) for 
1 h. MDAH‑2774 cells were incubated overnight at 4˚C with 
mTOR primary rabbit monoclonal antibody (catalog no. 2983, 
cell Signalling Technology, Inc.), followed by the addition of 
a secondary anti-rabbit Alexa Fluor® 488) (Thermo Fisher 
Scientific, Pittsburgh, PA, USA; dilution 1:400) and visualisa-
tion as previously described (20). ImageJ software was used to 
analyse the staining intensity. For each image, 10 individual 
cells were captured using the freehand tool, ensuring that the 
area for each cell was kept approximately the same. A back-
ground measurement for each image was calculated by taking 
an average measurement from 5 different areas across the 
image. This average background measurement was subtracted 
from each of the images, producing the final data that were 
used for statistical analysis. This process was repeated for all 
14 different images.
ImageStreamx Mark II flow cytometry. Whole blood (1 ml) 
from patient samples (n=3) was mixed with 9 ml of red blood 
cell lysis (RBc) buffer (G Biosciences, St. Louis, MO, USA), 
followed by incubation for 10 min with gentle agitation. 
Following centrifugation at 1,260 x g for 10 min at 4˚C the 
supernatant was discarded and 2 ml of RBc lysis buffer was 
added. This was followed by incubation for 10 min at room 
temperature with gentle agitation. Another centrifugation took 
Figure 1. An overview of mTOR signalling, including upstream and downstream regulators.
Table I. details of the mTOR pathway inhibitory agents used 
in this study.a 
Inhibitor concentrations
Rapamycin 20 nM  100 nM 
Everolimus 20 nM  100 nM 
deforolimus 100 nM  1,000 nM 
Temsirolimous 10 nM  100 nM 
Resveratrol 25 µM  50 µM 
BEZ235 10 nM  100 nM 
aInhibitor concentrations were chosen to reflect the range that other 
studies had found effective.
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place as previously described and the pellet was resuspended 
with 1.5 ml of PBS. The solution containing cTcs (and some 
white blood cells) was centrifuged at 1,450 x g for 3 min. 
The resulting cell pellet was resuspended in 1 ml of ice-cold 
4% paraformaldehyde for 7 min on ice and then centrifuged for 
5 min at 250 x g. Subsequent staining using specific antibodies 
against Rictor, Raptor and dEPTOR diluted in FBS-PBS 
(1:200) were used as previously described (24).
The qPcR data of the relative gene expression were analysed 
using the Δcq method whereby the cq value of the endogenous 
control was subtracted from the cq value of the gene of interest 
to calculate the Δcq and an RQ (relative quantity) value was 
calculated by finding 2-ΔΔcq (23). Where more than one refer-
ence gene was used, the RQ values were averaged.
Statistical analysis. data were presented as means ± SEM. All 
statistical tests were performed using Graph Pad Prism soft-
ware. If homoscedasticity (variance) of data was proven, an 
unpaired, two-tailed Student's t-test was performed to assess 
significance in all cases as no matched pairs of samples were 
used. If data were not homoscedastic, an unpaired, two-tailed 
Student's t-test with Welch's correction was performed to 
account for variance. Survival information for TcGA ovarian 
samples (n=426) was extracted from UcSc Xena browser 
repository (https://xenabrowser.net). Patient survival was 
measured in days to death or end-of-study. The samples were 
fractioned based on the mean gene expression value. The 
survival Kaplan-Meier curves were plotted in R using survfit 
function from bioconductor (https://bioconductor.org). P<0.05 
was considered statistically significant.
Results
Expression of mTOR, DEPTOR, Rictor and Raptor in endo‑
metriosis. qPcR for mTOR, DEPTOR, Rictor and Raptor was 
carried out using the reference genes RPL13A and YWHAZ 
in triplicate on cdNA synthesised from the extracted RNA 
from tissue of endometriosis patients and from non-affected 
controls. In endometriosis patients mTOR and Raptor, but not 
DEPTOR, showed a significant increase in expression (Fig. 2A, 
P≤0.0001 for both groups). Rictor showed no significant change 
overall but when segregated by age of patient (20-29 years 
and 30‑39 years) and grade points (<50 and >50) significant 
changes were evident. Rictor showed a significant increase in 
patients aged 20-29 years (P=0.0004) but not in patients aged 
30-39 years (Fig. 2B). We expanded our observations on the 
expression of mTOR components using liquid biopsies from 
ovarian cancer patients given that endometriosis is a risk factor 
for this malignancy. We observed that circulating tumour 
cells (cTcs) express Rictor, Raptor and dEPTOR (Fig. 2c).
Figure 2. qPCR for mTOR, DEPTOR, Rictor and Raptor was carried out in triplicate. Error bars ± SEM. mTOR and raptor showed a significant increase in 
expression compared to controls (A, P≤0.0001 for both groups). Rictor showed a significant increase in patients aged 20‑29 years (P=0.0004) (B). Expression 
of Rictor, Raptor and DEPTOR in CTCs using ImageStreamx Mark II flow cytometry. Channel 1: Brightfield of CTCs; Channel 2: Staining of CTCs with the 
nuclear marker dRAQ5 (red); channel 3: Expression of mTOR components (green); and channel 4: Merged images from channels 2 and 3 (c). ***P<0.001.
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Differential expression of mTOR and DEPTOR in ovarian 
cancer. We analysed the expression of mTOR and DEPTOR 
using the available RNAseq and microarray data. Specifically, 
we compared the expression of the two genes in various 
ovarian carcinomas using the Oncomine-curated dataset from 
Hendrix et al (25) (Fig. 2A and B). Both mTOR and DEPTOR 
showed an increase in the expression level compared to the 
control, across a variety of carcinomas, with mTOR being 
significantly upregulated in the ovarian endometrioid adeno-
carcinomas (Fig. 3A and B). In order to remove any potential 
bias induced by the small sample size of the Hendrix dataset 
(n=103), we examined the gene expression in ovarian serous 
cystadenocarcinoma samples from TcGA (n=428). As a 
control, we used the normal ovarian tissue samples from 
GTEX (n=88). All the data were extracted from the UcSc 
Xena repository. Ovarian samples from TcGA and GTEX 
were mapped, processed, quantified, and normalised using 
the same pipeline as described in Vivian et al (26). As previ-
ously observed in the endometrioid dataset, both mTOR 
and DEPTOR showed a statistically significant increase in 
the expression level in cancer samples compared to normal 
(p-val=5.26e-13 and 3.43e-13, respectively) (Fig. 3c and d). 
In terms of overall survival, we examined the Kaplan-Meier 
plots for the ovarian serous cystadenocarcinoma data from 
TcGA (n=426). The samples were separated into high and low 
expression levels, respectively, based on the mean expression 
across the entire dataset (Fig. 3E and F). We observed that 
in the case of mTOR, a higher expression level is associated 
Figure 3. Expression levels of (A) mTOR and (B) dEPTOR in Hendrix dataset. 1) control (n=4); 2) Ovarian clear cell Adenocarcinoma (n=8); 3) Ovarian 
Endometrioid Adenocarcinoma (n=37); 4) Ovarian Mucinous Adenocarcinoma (n=13), 5) Ovarian Serous Adenocarcinoma (n=41). Boxplots showing the 
average expression level of the mTOR (c) and DEPTOR (d) genes in ovarian samples from TcGA serous cystadenocarcinoma and GTEX. The expression level 
unit is shown as a log2 transformed of the normalised count +1, in order to facilitate cross-dataset comparison. Kaplan-Meier plots of overall survival (days) 
for higher and respectively lower than the mean expression level for mTOR (E) and dEPTOR (F).
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with a lower survival rate. By contrast, DEPTOR suggests that 
an increase in expression level is beneficial to the organisms' 
survival. However, this result is not statistically significant.
We expanded on these observations by assessing the 
protein expression of the two key components of mTORc1 and 
mTORc2 complexes using tissue microarray. mTOR expres-
sion at the protein level was identified throughout the stages 
of ovarian cancer with very little fluctuation. DEPTOR, on 
the other hand, showed a significant downregulation when we 
compared stages III and IV to stages I and II (Fig. 4A and B).
Effects of rapalogues on mTORC1 and mTORC2 components 
in vitro. Based on our clinical findings, it is evident that both 
mTOR and DEPTOR are involved in ovarian cancer. For this 
Figure 4. Immunohistochemistry for mTOR (A) and DEPTOR (B) was performed on paraffin‑embedded ovarian tissue clinical samples from stage I‑IV 
ovarian tumours. Error bars depict standard error. A significant difference was detected between early stage and late stage disease (P=0.0109). Panels Ai‑Aii 
and Bi-Bii show representative images of stage I and stage IV serous papillary carcinoma respectively for mTOR and dEPTOR.
Figure 5. Relative dEPTOR expression was measured by qPcR in MdAH-2774 cells treated with Rap (A, 20 and 100 nM), Eve (B, 20 and 100 nM), def 
(c, 100 and 1,000 nM), Tem (d, 10 nM and 100 nM), Res (E, 25 and 50 µM), BEZ (F, 10 and 100 nM) and carrier (dMSO) only control for 48 and 72 h. cdNA 
was synthesised from extracted RNA from 3 biological replicates for each condition *P<0.05, **P<0.01, ***P<0.001.
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reason, we investigated the effects of rapalogues on mTORc1 
and mTORc2 components in vitro, using the ovarian cancer cell 
line of endometrioid origin MdAH-2774 as an experimental 
model. MdAH-2774 cells were treated with Rapamycin, as well 
as the rapalogues Everolimus, deforolimus, and Temsirolimus, 
NVP-BEZ235 and resveratrol. All the treatments led to a 
significant increase in the gene expression of DEPTOR (Fig. 5).
Subsequently, we assessed the expression of Raptor. 
MdAH-2774 cells showed an overall trend towards decreasing 
Raptor expression in response to mTOR pathway inhibition 
(Fig. 6). Rapamycin and Everolimus treatment induced no 
change in expression at any time point or in response to high 
or low concentrations in MdAH-2774 cells. deforolimous 
treatment (1,000 nM) induced a decrease in raptor expression 
after 48 h of treatment in comparison to the controls (Fig. 6c, 
P=0.0067). Temsirolimous treatment (10 nM) induced a 
decrease in raptor expression after 48 and 72 h of treatment 
in MdAH-2774 cells in comparison to the controls (Fig. 6d, 
P=0.0457 and 0.0101, respectively). In addition, 100 nM Tem 
treatment induced a decrease in Raptor expression after 48 h of 
treatment (Fig. 6d, P=0.0115). Resveratrol treatment (25 µM) 
resulted in a decreased raptor expression after 72 h in comparison 
to controls and 50 µM Res treatment had the same effect after 
48-h treatment (Fig. 6E, P=0.0412 and 0.0318, respectively). 
BEZ treatment (10 nM) induced a decrease in Raptor expression 
after 48 h of treatment and 100 nM BEZ treatment resulted in 
decreased raptor expression after 72 h in comparison to controls 
(Fig. 6F, P=0.012 and 0.0298, respectively).
We also assessed the phosphorylation status of PRAS40 
and the protein expression of GβL on MdAH-2774 cells treated 
with Rapamycin, deforolimus, Resveratrol, Everolimus and 
Temsirolimus. Little change was observed at 48 h; however, 
a reduction of phospho-PRAS40 following treatment with 
Rapamycin, deforolimus, Everolimus and Temsirolimus 
was evident. Similarly, a slight decrease in GβL following 
rapamycin treatment was also identified (data not shown).
Interestingly, although the same treatments did not signifi-
cantly alter mTOR mRNA expression (data not shown), the 
dual kinase inhibitor NVP‑BEZ235 as well rapamycin signifi-
cantly decreased its protein expression at 48 h (Fig. 7). It is 
evident, therefore, that the differential expression of mTOR 
and dEPTOR is crucial for the activity of the complexes.
Discussion
In this study we provide evidence of differential expression 
of mTOR components in patients with endometriosis and 
ovarian cancer, and how rapalogues, including dual kinase 
inhibitors, can alter the expression of mTOR and dEPTOR. 
collectively our data suggest a crucial role for dEPTOR in 
ovarian cancer. In patients with endometriosis there was a 
significant increase in the expression of mTOR and Raptor 
as compared to the controls. Rictor did not show a significant 
change in overall expression, indicating the involvement of 
mTORC1 rather than mTORC2. However, Rictor was signifi-
cantly increased only in those aged 20-29 years. Proliferative 
Figure 6. Relative Raptor expression was measured by qPcR in MdAH-2774 cells treated with Rap (A, 20 and 100 nM), Eve (B, 20 and 100 nM), def (c, 100 and 
1,000 nM), Tem (d, 10 and 100 nM), Res (E, 25 and 50 µM), BEZ (F, 10 and 100 nM) and carrier (dMSO) only control for 48 and 72 h. *P<0.05, **P<0.01, ***P<0.001.
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diseases of the endometrium such as endometriosis and cancer 
are estrogen-dependent. It is possible that steroids affect the 
expression and subsequent activity of mTOR pathway. In 
a recent study, it was shown that the activation of protein 
synthesis in mouse uterine epithelial cells by estradiol-17β is 
mediated via a PKc-ERK1/2-mTOR signalling pathway (27). 
In breast cancer, Rictor's expression was higher in estrogen 
receptor-positive cases than in estrogen receptor-negative 
cases. Similarly, there is a direct link between mTORc1 and 
ERα, since mTORc1 directly phosphorylates and activates 
ERα upon estrogen stimulation (28). In a large meta-analysis 
involving 444,255 patients from 1,625 relevant studies, 
endometriosis was strongly associated with the increased 
risk of ovarian cancer, and endometriosis-associated ovarian 
cancer (EAOc) showed favourable characteristics including 
early‑stage disease, and a specific histology such as endome-
trioid or clear cell carcinoma (29).
The shift or change from endometriosis to ovarian cancer 
has been suggested to involve the mTOR pathway (30-35). 
deletion of PTEN, a tumour suppressor gene upstream of 
mTOR and involved in the PI3 kinase/Akt/mTOR axis in 
mice, induced ovarian endometrioid adenocarcinoma. In 
addition, the combination of K-Ras phosphorylation and 
PTEN deletion induced the phosphorylation of Akt, mTOR 
and p70S6 kinase indicating that the mTOR pathway, either 
by PI3 kinase/Akt or Ras/MAP kinase activation is involved 
in the transformation of endometriosis to ovarian cancer (30). 
This is further supported by the frequent downregulation of 
PTEN found in ovarian cancers (31,32) and increased K-Ras 
activation in endometriosis (33,34). In a more recent study 
using targeted next generation sequencing, it was shown that 
the PI3K-AKT-mTOR pathway may promote cell malignant 
transformation towards EAOc (35).
In the present study, a common pattern of expression was 
seen between ovarian cancer and endometriosis. We observed 
an increase in mTOR and Raptor expression in endometriosis, 
suggesting that mTOR complex 1 is involved in this condition 
as Raptor is an exclusive component of mTORc1. Previous 
findings have shown that, DEPTOR is involved in the patho-
genesis of human malignancies, primarily via its inhibitory 
role towards mTORc1 and mTORc2 (36,37). In addition, 
dEPTOR is underexpressed in many types of cancer including 
that of the prostate, bladder, and cervix, but it is overexpressed 
in multiple myelomas, thyroid cancers, and taxol-resistant 
ovarian cancer cell lines (28,36,38).
In the present study, although we did not observe any 
marked changes in the expression of dEPTOR in either endo-
metriosis or ovarian cancer patients, there was a significant 
decrease in its protein expression when we compared stages I 
and II to III and IV in ovarian cancer patients. This is consistent 
with the notion that deregulation of dEPTOR can contribute 
towards a ‘hyperactive’ mTOR pathway in cancer (39). 
dEPTOR can also be of prognostic value towards overall 
survival, since upregulation correlates positively with better 
Figure 7. Effects of Rapamycin (A) and BEZ (B) on mTOR protein expression in MdAH-2774 cells. *P<0.05, **P<0.01. Error bars ± SEM. Panels (c-E) are 
photomicrographs of MdAH cells treated with rapamycin and BEZ compared to the control.
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prognosis. These data corroborate a previous study showing 
that dEPTOR expression is an independent prognostic marker 
for thyroid carcinoma (38). It has also been considered as a 
predictive biomarker for therapeutic response in MM patients 
treated with thalidomide (40). However, to date, the exact role 
of dEPTOR remains controversial due to its ability to function 
as an oncogene and as a tumour-suppressor gene, depending 
on its cellular or tissue distribution (40).
Our study opens prospects for the use of dEPTOR, Rictor, 
and Raptor as potential biomarkers. Over the past years, the 
concept of liquid biopsies has been introduced as an alterna-
tive to conventional tissue biopsy. circulating tumour cells 
(cTcs) are cells that invade into the bloodstream from the 
primary tumours in the abdominal cavity (41,42). These cells 
are different to normal circulating blood cells and express 
tumour‑specific characteristics. CTCs are of diagnostic value 
in various types of cancer, but the clinical value of cTcs in 
ovarian cancer remains to be determined.
In order to gain better insight, we have used the MdAH-2774 
endometrioid ovarian cancer cell line as a preclinical model to 
study the mTOR pathway in basal state and upon inhibition 
using a wide repertoire of rapalogues, resveratrol and a dual 
kinase inhibitor. The findings showed that, inhibition of the 
mTOR pathway causes a shift of the dEPTOR/mTOR gene 
ratio. Moreover, rapamycin and NVP-BEZ downregulated the 
protein expression of mTOR. We hypothesise that dEPTOR 
overexpression counteracts mTOR activity acting as a poten-
tial drug target. Previous studies have already demonstrated 
that use of rapalogues can be of therapeutic potential in 
ovarian cancer. Everolimus inhibited the proliferation of 
human ovarian cancer cells, and prolonged survival in an 
ovarian cancer mouse model in vivo (43). A more detailed 
analysis of mTORc1 and mTORc2 signalling must be carried 
out to fully explore the extent to which each pathway is active 
in endometriosis and ovarian cancer using appropriate in vivo 
models with a view to identify the most appropriate drug 
targets. Indeed, rapalogues, which robustly inhibit mTORc1 
signalling but have little effect on mTORc2 signalling have 
not demonstrated any advances in cancer treatment that 
was expected from them, with few licenced uses for malig-
nancy (14). Moreover, performing colocalization experiments 
on dEPTOR with mTORc1 and mTORc2 components under 
basal conditions and in the presence of mTOR inhibitors 
allows us to further understand the stoichiometry of dEPTOR 
within the mTOR complexes.
The present study is a proof-of-concept pilot study. This 
research can be extended in the future with the use of primary 
cell lines, pending ethical approval. Moreover, future studies 
would provide better insight into the role of mTOR inhibitors 
(including dual inhibitors and resveratrol) in the expression 
of key components such as Protor or mSIN1 at the gene or 
protein level. Moreover, to the best of our knowledge, we 
have mapped for the first time, the expression of DEPTOR, 
Rictor and Raptor in cTcs. Future studies should demonstrate 
whether their expression can be used as a novel biomarker for 
diagnostic or prognostic purposes.
Upregulation of dEPTOR is a positive prognostic marker in 
ovarian cancer and is increased in response to mTOR pathway 
inhibition suggesting that it functions as a tumour suppressor 
gene in endometrioid ovarian carcinoma. collectively, our data 
suggest the mTOR pathway as a potential connection between 
endometriosis and ovarian cancer and may be a potential 
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